Patents by Inventor Patrick Salmon
Patrick Salmon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11649455Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.Type: GrantFiled: April 1, 2019Date of Patent: May 16, 2023Assignees: UNIVERSITY OF GENEVA, LES HÔPITAUX UNIVERSITAIRES DE GENÈVE, UNIVERSITY OF ZURICHInventors: Karl-Heinz Krause, Francis Rousset, Patrick Salmon, Marco Alessandrini, Roberto Speck, Simon Bredl, Tafadzwa Mlambo, Renier Myburgh
-
Patent number: 11613747Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.Type: GrantFiled: April 1, 2019Date of Patent: March 28, 2023Assignees: UNIVERSITY OF GENEVA, LES HÔPITAUX UNIVERSITAIRES DE GENÈVE, UNIVERSITY OF ZURICHInventors: Karl-Heinz Krause, Francis Rousset, Patrick Salmon, Marco Alessandrini, Roberto Speck, Simon Bredl, Tafadzwa Mlambo, Renier Myburgh
-
Publication number: 20220265727Abstract: The present invention relates to immortalized human cells particularly useful for cell encapsulation therapy and methods of preparation and use thereof.Type: ApplicationFiled: August 12, 2020Publication date: August 25, 2022Inventors: AURÉLIEN LATHUILIÈRE, NICOLAS MACH, PATRICK SALMON
-
Publication number: 20210095278Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.Type: ApplicationFiled: April 1, 2019Publication date: April 1, 2021Applicants: UNIVERSITY OF GENEVA, LES HÔPITAUX UNIVERSITAIRES DE GENÈVE, UNIVERSITY OF ZURICHInventors: Karl-Heinz KRAUSE, Francis ROUSSET, Patrick SALMON, Marco ALESSANDRINI, Roberto SPECK, Simon BREDL, Tafadzwa MLAMBO, Renier MYBURGH
-
Patent number: 10226538Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: GrantFiled: July 31, 2017Date of Patent: March 12, 2019Assignee: Research Development FoundationInventors: Didier Trono, Patrick Salmon
-
Publication number: 20170333573Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: ApplicationFiled: July 31, 2017Publication date: November 23, 2017Applicant: Research Development FoundationInventors: Didier TRONO, Patrick SALMON
-
Patent number: 9731033Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: GrantFiled: September 12, 2016Date of Patent: August 15, 2017Assignee: Research Development FoundationInventors: Didier Trono, Patrick Salmon
-
Patent number: 9556433Abstract: Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided.Type: GrantFiled: September 13, 2013Date of Patent: January 31, 2017Assignees: Université de Genève, University of PretoriaInventors: Karl-Heinz Krause, Renier Myburgh, Patrick Salmon
-
Publication number: 20160375152Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: ApplicationFiled: September 12, 2016Publication date: December 29, 2016Applicant: Research Development FoundationInventors: Didier TRONO, Patrick SALMON
-
Patent number: 9476062Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: GrantFiled: April 22, 2015Date of Patent: October 25, 2016Assignee: Research Development FoundationInventors: Didier Trono, Patrick Salmon
-
Publication number: 20160068862Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: ApplicationFiled: April 22, 2015Publication date: March 10, 2016Applicant: Research Development FoundationInventors: Didier TRONO, Patrick SALMON
-
Publication number: 20160010094Abstract: Methods for selecting transgenic cells comprising two or more drug resistance genes with a combination of cytotoxic drugs (e.g., trimetrexate (TMTX) and hydroxyurea (HU)). Such selection can be completed in vitro or in vivo. Transgenic cells and vectors comprising combinations of resistance genes are also provided. Transgenic cells of the embodiments can be used as cell based therapeutics, such as for treatment of HIV infection.Type: ApplicationFiled: February 28, 2014Publication date: January 14, 2016Applicants: UNIVERSITY OF PRETORIA, UNIVERSITE DE GENEVEInventors: Karl-Heinz Krause, David Suter, Patrick Salmon, Renier Myburgh, Michael Pepper
-
Patent number: 9103406Abstract: A vee-shaped transmission belt (1) has a main core (10) in the shape of a trapezium made of natural and/or synthetic rubber, containing at least one substantially inextensible cord (20) extending over the entire length of the belt (1). At least one layer (14) of fiber-reinforced elastomer is placed in contact with the core (10) near the long base (2) of the trapezium. At least one thin external coating layer (18) envelopes the entirety of the core (10) and the reinforced layer (14) over the entire length of the belt (1). A peripheral cushion (17) made of an elastomer that is elastically softer and more deformable than the core (10) surrounds the core (10) and the layer (14) of fiber-reinforced elastomer and is surrounded by the coating layer (18).Type: GrantFiled: October 16, 2012Date of Patent: August 11, 2015Assignee: Colmant Cuveiler SAInventor: Patrick Salmon
-
Publication number: 20150176006Abstract: Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided.Type: ApplicationFiled: September 13, 2013Publication date: June 25, 2015Applicants: UNIVERSITY OF PRETORIA, UNIVERSITE DE GENEVEInventors: Karl-Heinz Krause, Renier Myburgh, Patrick Salmon
-
Patent number: 9023646Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1 ? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: GrantFiled: September 9, 2013Date of Patent: May 5, 2015Assignee: Research Development FoundationInventors: Didier Trono, Patrick Salmon
-
Publication number: 20140243135Abstract: A vee-shaped transmission belt (1) has a main core (10) in the shape of a trapezium made of natural and/or synthetic rubber, containing at least one substantially inextensible cord (20) extending over the entire length of the belt (1). At least one layer (14) of fiber-reinforced elastomer is placed in contact with the core (10) near the long base (2) of the trapezium. At least one thin external coating layer (18) envelopes the entirety of the core (10) and the reinforced layer (14) over the entire length of the belt (1). A peripheral cushion (17) made of an elastomer that is elastically softer and more deformable than the core (10) surrounds the core (10) and the layer (14) of fiber-reinforced elastomer and is surrounded by the coating layer (18).Type: ApplicationFiled: October 16, 2012Publication date: August 28, 2014Inventor: Patrick Salmon
-
Publication number: 20140220678Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: ApplicationFiled: September 9, 2013Publication date: August 7, 2014Inventors: Didier TRONO, Patrick SALMON
-
Patent number: 8551773Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: GrantFiled: September 18, 2012Date of Patent: October 8, 2013Assignee: Research Development FoundationInventors: Didier Trono, Patrick Salmon
-
Patent number: 8338168Abstract: The present invention provides improved chimeric glycoproteins (GPs) and improved lentiviral vectors pseudotyped with those glycoproteins. Also provided are methods and compositions for making such glycoproteins and vectors, and improved methods of in vitro and in vivo transduction of cells with such vectors. Improved chimeric GPs encode the extracellular and transmembrane domains of GALV or RD114 GPs fused to the cytoplasmic tail of MLV-A GP. Vectors pseudotyped with these GAL V/TR and RD 114/TR GP chimeras have significantly higher titers than vectors coated with the parental GPs. Additionally, RD114/TR-pseudotyped vectors are efficiently concentrated and are resistant to inactivation induced by the complement of both human and macaque sera. RD114 GP-pseudotyped lentiviral vectors have particular utility for in vivo gene transfer applications.Type: GrantFiled: April 25, 2003Date of Patent: December 25, 2012Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Clayton de la RechercheInventors: Didier Trono, Francois-Loic Cosset, Virginie Sandrin, Bertrand Boson, Didier Negre, Patrick Salmon
-
Patent number: 8329462Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosaftey and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: GrantFiled: August 7, 2009Date of Patent: December 11, 2012Assignee: Research Development FoundationInventors: Didier Trono, Patrick Salmon